To this aim GLO1 polymorphism, AP and oxidative stress biomarkers (ROS, reduced glutathione, GSH, malonyldialdheyde, MDA) [20] levels were, firstly, studied in human differently aggressive and invasive LNCaP and PC3 prostate cancer cell lines, secondly, in urine sediments [21], [22] and blood of PCa and Benign Prostatic Hyperplasia (BPH) men, or healthy male age-matched subjects. The gene discussed is GLO1; the disease is benign prostatic hyperplasia.